|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy(STRATEGY):a multicenter,randomized,controlled,non-inferiority clinical trial显示文摘Despite the current guideline's recommendation of a timely stepwise intensification therapy,the 'clinical inertia',termed as the delayed treatment intensification,commonly exists in the real world,which may be partly due to the relatively little substantial evidence and no clear consensus regarding the efficacy and safety of triple oral agents in patients inadequately controlled with dual therapy.In this clinical trial performed in 237 centers in China,5,535 type 2 diabetic patients inadequately controlled by previous therapies were treated with a stable metformin/sitagliptin dual therapy for 20 weeks.The patients who did not reach the glycated hemoglobin A1c(HbA1c) goal were then further randomized into glimepiride,gliclazide,repaglinide,or acarbose group for an additional 24-week triple therapy.A mean HbAlc reduction of 0.85%was observed when sitagliptin was added to the patients inadequately controlled with metformin in 16 weeks.Further HbAlc reductions in the 24-week triple therapy stage were 0.65%in glimepiride group,0.70%in gliclazide group,0.61%in repaglinide group,and 0.45%in acarbose group.The non-inferiority criterion for primary hypotheses was met for gliclazide and repaglinide,but not for acarbose,compared with glimepiride,when added to metformin/sitagliptin dual therapy.The incidences of adverse events(AEs) were 29.2%in the dual therapy stage and30.3%in the triple therapy stage.Metformin/sitagliptin as baseline therapy,with the addition of a third oral antihyperglycemic agent,including glimepiride,gliclazide,repaglinide,or acarbose,was effective,safe and well-tolerated for achieving an HbAlc<7.0%goal in type 2 diabetic patients inadequately controlled with previous therapies.The timely augmentation of up to three oral antihyperglycemic agents is valid and of important clinical benefit to prevent patients from exposure to unnecessarily prolonged hyperglycemia. | Wen Xu Yiming Mu Jiajun Zhao Dalong Zhu Qiuhe Ji Zhiguang Zhou Bin Yao Anhua Mao Samuel S.Engel Bin Zhao Yan Bi Longyi Zeng Xingwu Ran Juming Lu Linong Ji Wenying Yang Weiping Jia Jianping Weng | 2017 | Science China(Life Sciences)2017，60，3： | 19 |
| 2 | Ectopic osteogenesis and angiogenesis regulated by porous architecture of hydroxyapatite scaffolds with similar interconnecting structure in vivo显示文摘The macro-pore sizes of porous scaffold play a key role for regulating ectopic osteogenesis and angiogenesis but many researches ignored the influence of interconnection between macro-pores with different sizes.In order to accurately reveal the relationship between ectopic osteogenesis and macro-pore sizes in dorsal muscle and abdominal cavities of dogs,hydroxyapatite(HA)scaffolds with three different macro-pore sizes of 500–650,750–900 and 1100–1250 mm were prepared via sugar spheres-leaching process,which also had similar interconnecting structure determined by keeping the d/s ratio of interconnecting window diameter to macro-pore size constant.The permeability test showed that the seepage flow of fluid through the porous scaffolds increased with the increase of macro-pore sizes.The cell growth in three scaffolds was not affected by the macro-pore sizes.The in vivo ectopic implantation results indicated that the macro-pore sizes of HA scaffolds with the similar interconnecting structure have impact not only the speed of osteogenesis and angiogenesis but also the space distribution of newly formed bone.The scaffold with macro-pore sizes of 750–900 mm exhibited much faster angiogenesis and osteogenesis,and much more uniformly distribution of new bone than those with othermacro-pore sizes.This work illustrates the importance of a suitable macro-pore sizes in HA scaffolds with the similar interconnecting structure which provides the environment for ectopic osteogenesis and angiogenesis. | Jinyu Li Wei Zhi Taotao Xu Feng Shi Ke Duan JianxinWang Yandong Mu Jie Weng | 2016 | Regenerative Biomaterials2016，3，5： | 16 |
| 3 | Role of polymorphisms of the IGF2 and IGFBP3 genes and risk of gastric carcinoma in China显示文摘 | Gu Jun Li Maolan Dong Ping Lu Jianhua Tan Zhujun Wu Xiangsong Mu Jiasheng Zhang Lin Wu Wenguang Ding Qichen Yang Jiahua Cao Yang Ding Qian Weng Hao Liu Yingbin | 2014 | Chinese Medical Journal2014，，3： | 2 |
| 4 | Sequence and analysis of rice chromosome 4 显示文摘 | Feng Q Zhang Y Hao P Wang S Fu G Huang Y Li Y Zhu J Liu Y Hu X Jia P Zhang Y Zhao Q Ying K Yu S Tang Y Weng Q Zhang L Lu Y Mu J Lu Y Zhang LS Yu Z Fan D Liu X Lu T Li C Wu Y Sun T Lei H Li T Hu H Guan J Wu M Zhang R Zhou B Chen Z Chen L Jin Z Wang R Yin H Cai Z Ren S Lv G Gu W Zhu G Tu Y Jia J Zhang Y Chen J Kang H Chen X Shao C Sun Y Hu Q Zhang X Zhang W Wang L Ding C Sheng H Gu J Chen S Ni L Zhu F Chert W Lan L Lai Y Cheng Z Gu M Jiang J Li J Hong G Xue Y Han B | 2002 | Nature2002，420，： | 1 |
| 5 | Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion显示文摘 | Maolan Li Jun Shen Xiangsong Wu Bingtai Zhang Rui Zhang Hao Weng Qian Ding Zhujun Tan Guofeng Gao Jiasheng Mu Jiahua Yang Yijun Shu Runfa Bao Qichen Ding Wenguang Wu Yang Cao Yingbin Liu | 2013 | Medical Oncology2013，，2： | 1 |
| 6 | The Remains of Ancient Tibetan and the Primitive Tibetan-Burman Language in Khampa Tibetan Dawu Dialect显示文摘I.Phonetics A.Consonant cluster Dawu area is located in the Hengduan Mountains region.Its terrain is complex with high mountains and low valleys.In the long historical period,because of the hostile natural environment and inconvenient transportation,people of Dawu area rarely communicated with people from other areas.In addition,Dawu dialect is a unique language,different | Gen Ga Weng Mu | 2015 | China Tibetology2015，，2： | 0 |
| 7 | Structural insights into ligand recognition and selectivity of somatostatin receptors显示文摘Somatostatin receptors(SSTRs)play versatile roles in inhibiting the secretion of multiple hormones such as growth hormone and thyroid-stimulating hormone,and thus are considered as targets for treating multiple tumors.Despite great progress made in therapeutic development against this diverse receptor family,drugs that target SSTRs still show limited efficacy with preferential binding affinity and conspicuous side-effects.Here,we report five structures of SSTR2 and SSTR4 in different states,including two crystal structures of SSTR2 in complex with a selective peptide antagonist and a non-peptide agonist,respectively,a cryo-electron microscopy(cryo-EM)structure of Gi1-bound SSTR2 in the presence of the endogenous ligand SST-14,as well as two cryo-EM structures of Gi1-bound SSTR4 in complex with SST-14 and a small-molecule agonist J-2156,respectively.By comparison of the SSTR structures in different states,molecular mechanisms of agonism and antagonism were illustrated.Together with computational and functional analyses,the key determinants responsible for ligand recognition and selectivity of different SSTR subtypes and multiform binding modes of peptide and non-peptide ligands were identified.Insights gained in this study will help uncover ligand selectivity of various SSTRs and accelerate the development of new molecules with better efficacy by targeting SSTRs. | Wenli Zhao Shuo Han Na Qiu Wenbo Feng Mengjie Lu Wenru Zhang Mu Wang Qingtong Zhou Shutian Chen Wei Xu Juan Du Xiaojing Chu Cuiying Yi Antao Dai Liaoyuan Hu Michelle YShen Yaping Sun Qing Zhang Yingli Ma Wenge Zhong Dehua Yang Ming-Wei Wang Beili Wu Qiang Zhao | 2022 | Cell Research2022，32，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员